Significance of viral status on prognosis of hepatitis B‐related hepatocellular carcinoma after curative resection in East Asia

Qu, Lei; Zhang, Haifeng

doi:10.1111/hepr.12523

Cited by 7 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that chronic hepatitis B virus (HBV) infection is a major risk factor for the development of cirrhosis and HCC [5]. High hepatitis B surface antigen (HBsAg) levels and high serum HBV DNA load were found to increase the risk of HBV-related cirrhosis and HCC significantly [6, 7]. Basic research found that HBV-initiated tumorigenesis may play a role in the development of HCC microvascular invasion [8, 9].…”

Section: Introductionmentioning

confidence: 99%

Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma

Huang

Liu

et al. 2019

Infect Agents Cancer

View full text Add to dashboard Cite

BackgroundChronic hepatitis B virus (HBV) infection is a major risk factor for the occurrence and development of cirrhosis and hepatocellular carcinoma (HCC). Microvascular invasion (MVI) of HCC is closely related to postoperative recurrence. We aimed to investigate the effect of HBV DNA replication levels and anti-HBV treatment on the occurrence of MVI in HCC.MethodsA retrospective analysis of the clinical and pathological data of 660 patients undergoing hepatectomy for hepatocellular carcinoma at the Affiliated Hospital of Qingdao University from January 2015 to December 2017 is included in this study.ResultsThis study involved a total of 660 patients with an MVI incidence rate of 46.8% (309/660). Univariate analysis revealed that positive HBV surface antigen (HBsAg), detectable HBV DNA load, and administration of antiviral treatment were significantly associated with the formation of MVI. Multivariable logistic regression analysis in patients with positive seral HBsAg showed that detectable HBV DNA load (OR = 5.33, P < 0.001) was an independent risk factor for MVI. Antiviral treatment for more than six months (OR = 0.37, P = 0.002) was an independent protective factor against MVI. Patient groups with severe MVI had significantly higher rates of HBV infection (P = 0.017), a detectable HBV DNA load (> 100 IU/ml) rate (P < 0.001), and obvious low antiviral treatment rate (P = 0.021).ConclusionsHBV DNA replication level is an independent risk factors for the formation of HCC MVI, and anti-hepatitis B virus treatment has an inhibitory effect on MVI formation.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma

Huang

Liu

et al. 2019

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“…The age cut-off was set as 55: Young (aged <55 years) and old patients (aged ≥55 years). The grading system used was Edmondson grade (14). The TNM staging system refers to the newest NCCN guidelines (15).…”

Section: Methodsmentioning

confidence: 99%

Long non‑coding RNA BACE1‑AS is an independent unfavorable prognostic factor in liver cancer

Nie

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Liver cancer is one of the leading causes of cancer-associated deaths with incidence rates continuously on the rise. Biomarkers are urgently required for early diagnosis and better prognostic classification, which is essential for risk stratification and optimizing treatment strategies in clinical settings. By analyzing the data extracted from The Cancer Genome Atlas database using R, the long noncoding RNA (lncRNA) β-site APP-cleaving enzyme 1 antisense (BACE1-AS) was discovered to have both high diagnostic and prognostic values in liver cancer, which could serve as a promising biomarker in clinical settings. Precisely, lncRNA BACE1-AS is significantly overexpressed in liver cancer and its levels vary within different subgroups, suggesting its tumorigenic role. Furthermore, higher BACE1-AS predicts poorer overall survival and relapse-free survival outcomes. Overall, the present study demonstrated that BACE1-AS may be involved in liver cancer progression and could serve as a promising biomarker for diagnosis and prognostic evaluation.

show abstract

“…[ 6 ] Various factors, including a high load of HBV-DNA, are considered a risk for HCC recurrence after radical therapy. [ 7 ] In recent years, several studies have indicated that a high HBV-DNA load predicts HCC recurrence after curative resection. [ 8 , 9 ] However, few studies have evaluated the effectiveness of postoperative anti-HBV therapy on tumor recurrence.…”

Section: Introductionmentioning

confidence: 99%

Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy

Rui

Yan²,

Zhang³

et al. 2017

Medicine

View full text Add to dashboard Cite

Liver resection may be beneficial in intermediate-stage hepatocellular carcinoma (HCC), though the benefit of postoperative anti-hepatitis B virus (HBV) therapy in these patients remains unclear. In this study, we sought to evaluate the efficacy of postoperative anti-HBV for intermediate-stage HCC patients who underwent radical liver resection.According to inclusion and exclusion criteria, this study enrolled 202 HCC patients who underwent liver resection and had a high HBV-DNA load. The patients were divided into 2 groups on the basis of postoperative anti-HBV therapy: group A included patients undergoing postoperative anti-HBV therapy, whereas group B patients did not receive any postoperative anti-HBV therapy. Factors including baseline demographics, tumor characteristics, overall long-term survival, tumor-free survival, and tumor recurrence rate were compared between the 2 groups. Moreover, univariate and multivariate analyses were used to identify risk factors of HCC recurrence.Baseline demographics and tumor characteristics were comparable between the groups. The 1-, 3-, and 5-year overall survival rates in group A were 91.3%, 80.9%, and 66.1%, respectively, values that were significantly increased compared with group B (91.7%, 60.7%, and 52.4%, respectively, P = .019). Group A patients also exhibited enhanced 1-, 3-, and 5-year tumor-free survival compared with group B patients (87.0%, 67.0%, and 62.6%, respectively, in group A; 82.1%, 50.0%, and 42.9% in group B, P = .002). In addition, the tumor recurrence rate in group B was significantly increased compared with group A (P < .01). Univariate and multivariate analyses indicated lack of postoperative anti-HBV therapy [hazard ratio (HR) = 0.882; 95% confidence interval (CI), 0.712–0.938; P = .042] to be a predictor of tumor recurrence.For intermediate-stage [Barcelona Clinic Liver Cancer (BCLC) stage B] HCC with a high HBV-DNA load, postoperative anti-HBV therapy after curative resection should be routine adjuvant therapy.

show abstract

Significance of viral status on prognosis of hepatitis B‐related hepatocellular carcinoma after curative resection in East Asia

Cited by 7 publications

References 76 publications

Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma

Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma

Long non‑coding RNA BACE1‑AS is an independent unfavorable prognostic factor in liver cancer

Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy

Contact Info

Product

Resources

About